中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

221 records (took 0.037 seconds)

    Apparatus for and method of nuclear quadrupole resonance testing of a sample
    1.
    发明授权
    Apparatus for and method of nuclear quadrupole resonance testing of a sample 失效
    样品的核四极共振测试装置和方法

    公开(公告)号：US06166541A

    公开(公告)日：2000-12-26

    申请号：US5026

    申请日：1998-01-12

    Applicant: John Alec Sydney Smith ,  Simon Peter Beevor ,  Michael David Rowe

    Inventor： John Alec Sydney Smith ,  Simon Peter Beevor ,  Michael David Rowe

    IPC: G01R33/20 ,  G01N24/00 ,  G01N24/08 ,  G01R33/36 ,  G01R33/44 ,  G01V3/00

    CPC classification number: G01R33/3607 ,  G01R33/441

    Abstract: Apparatus for Nuclear Quadrupole Resonance testing a remote sample containing a given species of quadrupolar nucleus includes at least one probe (112) having a given maximum cross-sectional dimension; a device (102) for applying excitation to the probe or at least one of the probes to excite nuclear quadruple resonance for a selected range of distance of the sample from each such probe, the selected range being at least one tenth of the given maximum dimension of the probe, the apparatus being adapted to produce a non-uniform field over the selected range; and a device (106) for detecting the resonance response signal from the sample via the probe or at least one of the probes; the excitation being such as would generate non-zero resonance signals at all distances within the selected range.

    Abstract translation: 用于核四极共振的装置测试含有给定种类的四极核的远程样品包括具有给定最大横截面尺寸的至少一个探针（112）; 用于向所述探针或所述探针中的至少一个探针施加激励以在每个所述探针的所述样品的选定距离范围内激发核四重共振的装置（102），所述选定范围是给定最大尺寸的至少十分之一 所述装置适于在所述选定范围内产生非均匀场; 以及用于经由所述探针或所述探针中的至少一个检测来自所述样品的共振响应信号的装置（106） 激励将在所选范围内的所有距离处产生非零谐振信号。

    Seed priming
    2.
    发明授权
    Seed priming 失效
    种子启动

    公开(公告)号：US5873197A

    公开(公告)日：1999-02-23

    申请号：US809104

    申请日：1997-03-17

    Applicant: Hugh Robert Rowse ,  John Michael Terence McKee

    Inventor： Hugh Robert Rowse ,  John Michael Terence McKee

    IPC: A01C1/06 ,  A01C1/02

    CPC classification number: A01C1/06 ,  A01C1/02

    Abstract: A method for treating plant seed is provided comprising contacting them with a first surface of semi-permeable membrane having first and second surfaces, the second surface being in direct contact with a solution of predetermined osmotic potential, whereby the seeds abstract water from the solution through the membrane, wherein the seed and semi-permeable membrane are constantly or periodically caused to move relative to each other such as to constantly or periodically reorient the seed with respect to the first surface such that the transfer of water occurs evenly over substantially the entire surface area of the seed. For seed priming the osmotic pressure and the period for which the seeds are maintained in contact with the membrane are sufficient to allow pre-germinative metabolic processes to take place within the seeds up to a level limited to that immediately preceding radicle emergence. Methods for germinating seed and inducing desiccation tolerance in seed are also provided. Preferably the semi-permeable membrane is provided in the form of a tube of circular or polygonal cross-section which is rotated with the seeds on its inner surface and the solution retained between its outer surface and a further body to which the membrane is sealed in a watertight manner.

    Abstract translation: PCT No.PCT / GB95 / 02188 Sec。 371日期1997年3月17日 102（e）1997年3月17日PCT PCT 1995年9月15日PCT公布。 出版物WO96 / 08132 日期1996年3月21日提供了一种处理植物种子的方法，包括使其与具有第一和第二表面的半透膜的第一表面接触，第二表面与预定渗透势的溶液直接接触，由此种子抽象 来自溶液的水通过膜，其中种子和半透膜常常或周期性地相对于彼此移动，以使得种子相对于第一表面不断地或周期性地重新定向，使得水的均匀均匀地发生 在种子的基本上整个表面积上。 对于种子引发，渗透压力和种子保持与膜接触的时间足以使得种子内的发芽代谢过程发生在限于刚才胚根出现之前的水平。 还提供了种子发芽和诱导干燥耐受性的方法。 优选地，半透膜以圆形或多边形横截面的形式提供，其随着种子在其内表面上旋转并且溶液保持在其外表面和膜被密封到的另一个本体之间 水密的方式。

    Herpes simplex cirus type 1 mutant
    3.
    发明授权
    Herpes simplex cirus type 1 mutant 失效
    单纯疱疹病毒1型突变体

    公开(公告)号：US5837532A

    公开(公告)日：1998-11-17

    申请号：US435280

    申请日：1995-05-05

    Applicant: Christopher Maurice Preston ,  Christopher Ian Ace

    Inventor： Christopher Maurice Preston ,  Christopher Ian Ace

    IPC: A61K35/76 ,  A61K38/44 ,  A61K48/00 ,  A61P25/00 ,  A61P31/12 ,  A61P31/22 ,  A61P43/00 ,  C12N7/00 ,  C12N7/01 ,  C12N15/09 ,  C12N15/861 ,  C12N15/869 ,  C12N15/86

    CPC classification number: C12N15/86 ,  C12N7/00 ,  C12N2710/16621 ,  C12N2710/16643 ,  C12N2830/00 ,  C12N2830/60

    Abstract: A herpes simplex virus type I (HSV-1) mutant capable of establishing latent infection in the absence of in vivo viral replication in neuronal cells and of expressing an inserted therapeutic gene, which comprising: (i) a DNA sequence change in the gene coding for Vmw65 protein, such as to substantially remove the transducing properties while retaining its structural role and thereby preventing in vivo replication, the DNA sequence change being achieved by a transition or transversion alteration of 1 to 72 base pairs, an oligonucleotide insert of 3 to 72 base pairs, or a deletion of 3 to 72 base pairs, at a position between amino acids 289 and 412 of the protein; and (ii) a therapeutic gene inserted into a region of the HSV-1 genome which is non-essential for culture of the virus, and a promoter therefor able to express the therapeutic gene in neuronal cells in vivo. The preferred insertion site for the therapeutic gene (e.g. tyrosine hydroxylase gene) is within the thymidine kinase gene of HSV in 1814.

    Abstract translation: 一种单纯疱疹病毒I型（HSV-1）突变体能够在神经元细胞中不存在体内病毒复制和表达插入的治疗基因时建立潜伏感染，其包括：（i）编码基因的DNA序列变化 对于Vmw65蛋白质，例如基本上除去转导特性，同时保持其结构作用，从而防止体内复制，DNA序列变化通过1至72个碱基对的转换或颠换改变，3至72个碱基对的寡核苷酸插入物 碱基对，或缺失3至72个碱基对，位于蛋白质的氨基酸289和412之间; 和（ii）插入到HSV-1基因组区域中的治疗基因，其对于病毒的培养是非必需的，以及能够在体内在神经元细胞中表达治疗基因的启动子。 治疗基因（例如酪氨酸羟化酶基因）的优选插入位点在1814年的HSV的胸苷激酶基因内。

    Composition for treatment of plant material
    5.
    发明授权
    Composition for treatment of plant material 失效
    用于处理植物材料的组合物

    公开(公告)号：US5817600A

    公开(公告)日：1998-10-06

    申请号：US972365

    申请日：1997-11-18

    Applicant: Margaret L. Carstairs ,  Laurance W. I. Jennings

    Inventor： Margaret L. Carstairs ,  Laurance W. I. Jennings

    IPC: A01N3/00 ,  A01N3/02 ,  A01N43/90

    CPC classification number: A01N3/00 ,  A01N3/02

    Abstract: The invention relates to the use of one or more methyl xanthines to enhance the flower and foliage color of plant material and compositions therefor; compositions to promote the continued development of plant material comprising a methyl xanthine and a gibberellin; use of a composition comprising a methyl xanthine and a gibberellin to promote the continued development of plant material; and plant material treated with a composition as defined above

    Abstract translation: 本发明涉及一种或多种甲基黄嘌呤用于增强植物材料及其组合物的花和叶面颜色的用途; 用于促进包含甲基黄嘌呤和赤霉素的植物材料的持续发展的组合物; 使用包含甲基黄嘌呤和赤霉素的组合物来促进植物材料的持续发展; 和用上述组合物处理的植物材料

    Anti-cancer compounds
    7.
    发明授权
    Anti-cancer compounds 失效
    抗癌化合物

    公开(公告)号：US5747499A

    公开(公告)日：1998-05-05

    申请号：US732273

    申请日：1996-10-29

    Applicant: Vassilios Bavetsias ,  Francis Thomas Boyle ,  Laurent Francois Andre Hennequin ,  Jonathan Hugh Marriott

    Inventor： Vassilios Bavetsias ,  Francis Thomas Boyle ,  Laurent Francois Andre Hennequin ,  Jonathan Hugh Marriott

    IPC: A61K31/505 ,  A61K31/517 ,  A61P29/00 ,  A61P35/00 ,  A61P37/08 ,  A61P43/00 ,  C07D239/70 ,  C07D401/12 ,  C07D403/12 ,  C07D403/04

    CPC classification number: C07D401/12 ,  C07D239/70 ,  Y02P20/55

    Abstract: Cyclopentaquinazoline of the formula (I): ##STR1## wherein R.sup.1 is hydrogen, amino, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 hydroxyalkyl or C.sub.1-4 fluoroalkyl; wherein R.sup.2 is hydrogen, C.sub.1-4 alkyl, C.sub.3-4 alkenyl, C.sub.3-4 alkynyl, C.sub.2-4 hydroxyalkyl, C.sub.2-4 halogenoalkyl or C.sub.1-4 cyanoalkyl; Ar.sup.1 is phenylene, thiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl which may optionally bear one or two substituents selected from halogeno, hydroxy, amino, nitro, cyano, trifluoromethyl, C.sub.1-4 alkyl and C.sub.1-4 alkoxy; and wherein R.sup.3 is a group of the formula: --A.sup.1 --Ar.sup.2 --A.sup.2 --Y.sup.1 in which A.sup.1, A.sub.2, Y.sup.1 and Ar.sub.2 are defined in claim 1; or a pharmaceutically acceptable salt or ester there of are of therapeutic value particularly in the treatment of cancer.

    Abstract translation: PCT No.PCT / GB95 / 01016 Sec。 371日期1996年10月29日第 102（e）日期1996年10月29日PCT提交1995年5月4日PCT公布。 WO95 / 30673 PCT出版物 日期：1995年11月16日式（I）的环戊基喹唑啉：其中R 1是氢，氨基，C 1-4烷基，C 1-4烷氧基，C 1-4羟基烷基或C 1-4氟代烷基; 其中R2是氢，C1-4烷基，C3-4烯基，C3-4炔基，C2-4羟烷基，C2-4卤代烷基或C1-4氰基烷基; Ar 1是亚苯基，噻吩二基，噻唑二基，吡啶二基或嘧啶二基，其可任选地具有一个或两个选自卤代，羟基，氨基，硝基，氰基，三氟甲基，C 1-4烷基和C 1-4烷氧基的取代基; 并且其中R 3是下列基团：A 1 -A 2 -A 2 -Y 1 y其中A 1，A 2，Y 1和Ar 2如权利要求1中所定义; 或其药学上可接受的盐或酯具有治疗价值，特别是在治疗癌症中。

Patent Agency Ranking